Walleye Capital LLC Takes $134,000 Position in Tenaya Therapeutics, Inc. (NASDAQ:TNYA)

Walleye Capital LLC bought a new stake in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) during the third quarter, Holdings Channel reports. The institutional investor bought 69,479 shares of the company’s stock, valued at approximately $134,000.

A number of other institutional investors have also modified their holdings of TNYA. abrdn plc acquired a new position in shares of Tenaya Therapeutics in the 3rd quarter valued at $1,063,000. Renaissance Technologies LLC increased its holdings in shares of Tenaya Therapeutics by 144.1% in the 2nd quarter. Renaissance Technologies LLC now owns 157,460 shares of the company’s stock valued at $488,000 after acquiring an additional 92,960 shares during the period. Integral Health Asset Management LLC increased its holdings in shares of Tenaya Therapeutics by 3.3% in the 2nd quarter. Integral Health Asset Management LLC now owns 2,325,000 shares of the company’s stock valued at $7,208,000 after acquiring an additional 75,000 shares during the period. Squarepoint Ops LLC increased its holdings in shares of Tenaya Therapeutics by 86.0% in the 2nd quarter. Squarepoint Ops LLC now owns 120,704 shares of the company’s stock valued at $374,000 after acquiring an additional 55,816 shares during the period. Finally, Panagora Asset Management Inc. acquired a new position in shares of Tenaya Therapeutics in the 2nd quarter valued at $164,000. 90.54% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

TNYA has been the topic of several recent research reports. HC Wainwright reissued a “buy” rating and issued a $18.00 price objective on shares of Tenaya Therapeutics in a research note on Monday, November 25th. Chardan Capital dropped their price objective on shares of Tenaya Therapeutics from $20.00 to $18.00 and set a “buy” rating on the stock in a research note on Thursday, November 7th. Leerink Partners reissued an “outperform” rating on shares of Tenaya Therapeutics in a research note on Friday, October 18th. Canaccord Genuity Group reissued a “buy” rating and issued a $16.00 price objective on shares of Tenaya Therapeutics in a research note on Friday, October 18th. Finally, Piper Sandler reissued an “overweight” rating on shares of Tenaya Therapeutics in a research note on Friday, October 18th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $17.33.

Tenaya Therapeutics Stock Performance

Shares of NASDAQ TNYA opened at $3.66 on Thursday. The firm has a market capitalization of $289.95 million, a P/E ratio of -2.54 and a beta of 2.71. Tenaya Therapeutics, Inc. has a one year low of $1.61 and a one year high of $7.01. The company’s fifty day moving average is $2.40 and its two-hundred day moving average is $2.79.

Tenaya Therapeutics (NASDAQ:TNYA) last issued its earnings results on Wednesday, November 6th. The company reported ($0.30) EPS for the quarter, topping the consensus estimate of ($0.37) by $0.07. On average, sell-side analysts forecast that Tenaya Therapeutics, Inc. will post -1.35 earnings per share for the current fiscal year.

Tenaya Therapeutics Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.